Exosome Diagnostics Announces Appointment of William J. Kelly as Chief Financial Officer
NEW YORK, May 28, 2014 – Exosome Diagnostics, a leading developer of non-invasive, biofluid-based molecular diagnostics, today announced that William J. Kelly has been appointed as its chief financial officer, effective May 27, 2014.
Mr. Kelly, 43, has over 20 years of financial management experience, including the past 13 years leading growing, international, publicly traded life science companies. For the past six years, Mr. Kelly worked at RepliGen Corporation, where he was the company’s principal financial officer for more than five of those years, serving as either chief accounting officer or chief financial officer since 2008. Mr. Kelly played a vital role in transforming RepliGen from a research-and-development entity to a profitable, global, commercial life sciences company through a combination of acquisitions, new product launches and organic growth. During Mr. Kelly’s tenure at RepliGen, the market capitalization of the company increased from $100 million to $600 million and revenues increased from $14 million to $68 million.
From 2001 to 2008, Mr. Kelly was corporate controller of Haemonetics Corporation, currently a $1.7 billion market capitalization medical device company with operations in over twenty countries around the world. He was directly or indirectly responsible for a team of more than 100 finance personnel, oversaw all aspects of SEC and related compliance activities and led a global ERP implementation to drive operational efficiencies and support the company’s acquisition goals.
Mr. Kelly is a Certified Public Accountant. While working at Deloitte & Touche LLP in their Boston and Dublin, Ireland, audit practices, he helped lead clients through numerous initial and subsequent public offerings and acquisition transactions. He holds an M.S./M.B.A. from Northeastern University as well as a B.A. in psychology from the College of the Holy Cross.
About Exosome Diagnostics
Exosome Diagnostics is a leading developer of fluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are packaged and shed into all biofluids, including blood, urine and cerebrospinal fluid, providing a stable source for intact, disease-specific genetic material. The company’s proprietary exosome technology makes use of the presence and natural stability of RNA in exosomes to detect and measure levels of genes responsible for cancer and other diseases. For more information, please visit www.exosomedx.com.